You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Mechanistic Studies of a Novel Small Molecule HIV Inhibitor

    SBC: ADVANCED GENETIC SYSTEMS, INC.            Topic: 100

    DESCRIPTION provided by applicant There is a significant need for novel HIV therapies given the emergence of viruses resistant to existing drug regimens The Rev RRE protein RNA interaction in HIV plays an essential role in the transport of viral mRNA from the nucleus to the cytoplasm where it can be translated or packaged Previously we identified the thienopyridine scaffold that inhibited HIV ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a biomimetic small molecule therapeutic for neovascular retinal diseases

    SBC: EyeMedix, Inc.            Topic: N

    DESCRIPTION provided by applicant Retinal diseases including age related macular degeneration AMD diabetic retinopathy DR diabetic macular edema DME and retina vein occlusion RVO are the leading causes of vision loss and blindness in people over years old According to the NEI in nearly million people in the U S suffered from some form of these diseases whose prevalen ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Targeting C/EBP-beta Phosphorylation for the Treatment of Lung Fibrosis

    SBC: XFIBRA, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant Activation of lung myofibroblasts LMF is responsible for the development of lung fibrosis in chronic lung diseases of all causes and remarkably LMF clearance by apoptosis may prevent development of lung fibrosis and lung injury and possibly allow recovery from reversal of lung fibrosis There is full agreement among tissue fibrosis experts that inhibiting o ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors

    SBC: SignalRx Pharmaceuticals Inc.            Topic: 102

    DESCRIPTION provided by applicant There is an unmet need to inhibit the key cancer promoting transcription factor MYC MYC both cMYC and MYCN acts downstream of many cell receptor complexes and signal transduction pathways to activate genes that drive cancer cell growth and proliferation To date small molecule inhibitors of MYC have been elusive An innovative approach would be to indirectl ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Novel Membrane Protein Solubilization/Stabilization Screen

    SBC: SOLUBLE THERAPEUTICS, INC            Topic: 100

    DESCRIPTION provided by applicant The increasing output of new integral membrane protein IMP structures is partially due to the availability of an increasing number of chemical variables such as detergents detergent like molecules lipids and solubilizing stabilizing additives It is clear that specific combinations and concentrations of these different variables are often necessary to impr ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells

    SBC: ZoneOne Pharma            Topic: O

    DESCRIPTION provided by applicant The goal of this research is to develop a ligand product and facile method to use it to target FDA approved liposomal anticancer drugs to cancer stem cells that overexpress CD We have devised a highly efficient chemo enzymatic synthesis of a hyaluronan lipid HA lipid ligand and have teamed with ZoneOne Pharma to develop a simple and robust micelle transfer ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Breath ammonia monitoring device for children with urea cycle disorders

    SBC: Lumina Diagnostics, Inc.            Topic: NICHD

    DESCRIPTION provided by applicant We propose to develop a non invasive device to enable children with urea cycle disorders and their parents guardians and physicians to actively manage the disorder at home and improve outcomes in the clinic Urea cycle disorders UCD are inborn errors of metabolism that impair oneandapos s ability to convert ammonia NH a neurotoxin into urea which is ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. USE OF DNATrax TO MODEL THE TRANSPORT OF PARTICULATE MATTER IN URBAN ENVIRONMENTS

    SBC: DNATREK, LLC            Topic: NIEHS

    DESCRIPTION provided by applicant Science based strategies for quantifying and mitigating the impact of anthropogenic emissions on public health are essential for the sustainability of cities Similar strategies can also be used to develop and assess the effectiveness of a national defense system against terrorist attacks with airborne biological agents and protect against the spread of airborn ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Development of iCrystal System for Rapid Crystallization of Biological Macromolecules

    SBC: JUXTOPIA, LLC            Topic: 100

    DESCRIPTION provided by applicant Biological macromolecules are the machinery of life and understanding their function helps scientists to develop new drug treatments that target specific human diseases In this regard crystallization is routinely employed for the understanding of the molecular structures and the interactions of proteins with other biological and non biological materials Desp ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Developing efficient and safe cell-permeable reprogramming peptides for generation of iPS cells.

    SBC: Vivoscript, Inc.            Topic: 200

    DESCRIPTION provided by applicant The groundbreaking discovery of induced pluripotent stem cells iPSCs has opened a new page for developing personalized cell based therapies against various devastating human diseases without ethical concerns of using human embryonic stem cells However the future clinical applications of iPSCs remain in doubt due to potential risks of undesired genomic alter ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government